POTOMAC, MARYLAND, August 27, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: “Reports Q1 results. We believe more positive
POTOMAC, MD, August 25, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating
POTOMAC, MARYLAND – August 19, 2025 – IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease,
POTOMAC, MARYLAND – August 05, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments for Alzheimer’s and
– Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings –
POTOMAC, MARYLAND – July 21, 2025 – IGC Pharma, Inc. (NYSE American: IGC) a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D.,
Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer’s diagnostics
POTOMAC, MARYLAND – June 30, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and
POTOMAC, MARYLAND – June 27, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced that the Company will host a conference call and webcast on
We are presenting a poster named “Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay” at The Genetic Toxicology Association (GTA) Meeting 2025 held at the Clayton Hall